|
1
|
van de Rijn M and Fletcher JA: Genetics of
soft tissue tumors. Annu Rev Pathol. 1:435–466. 2006. View Article : Google Scholar
|
|
2
|
Maki RG: Gemcitabine and docetaxel in
metastatic sarcoma: past, present, and future. Oncologist.
12:999–1006. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tschoep K, Kohlmann A, Schlemmer M,
Haferlach T and Issels RD: Gene expression profiling in sarcomas.
Crit Rev Oncol Hematol. 63:111–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Werner M, Atil B, Sieczkowski E, Chiba P
and Hohenegger M: Simvastatin-induced compartmentalisation of
doxorubicin sharpens up nuclear topoisomerase II inhibition in
human rhabdomyosarcoma cells. Naunyn Schmiedebergs Arch Pharmacol.
386:605–617. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu YH, Kuo HP, Hsieh HH, et al: Ganoderma
tsugae induces S phase arrest and apoptosis in
doxorubicin-resistant lung adenocarcinoma H23/0.3 cells via
modulation of the PI3K/Akt signaling pathway. Evid Based Complement
Alternat Med. 2012:3712862012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
NCCN: Soft Tissue Sarcoma. NCCN
Guidelines. Version 1. 2012
|
|
7
|
Longhi A, Ferrari S, Tamburini A, et al:
Late effects of chemotherapy and radiotherapy in osteosarcoma and
Ewing sarcoma patients: the Italian Sarcoma Group Experience
(1983–2006). Cancer. 118:5050–5059. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang YW, Wang LS, Chang HL, et al:
Effects of serum on (-)-gossypol-suppressed growth in human
prostate cancer cells. Anticancer Res. 26:3613–3620.
2006.PubMed/NCBI
|
|
9
|
Lian J, Ni Z, Dai X, et al: Sorafenib
sensitizes (-)-gossypol-induced growth suppression in
androgen-independent prostate cancer cells via Mcl-1 inhibition and
Bak activation. Mol Cancer Ther. 11:416–426. 2012. View Article : Google Scholar
|
|
10
|
Pang X, Wu Y, Wu Y, et al: (-)-Gossypol
suppresses the growth of human prostate cancer xenografts via
modulating VEGF signaling-mediated angiogenesis. Mol Cancer Ther.
10:795–805. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Enyedy IJ, Ling Y, Nacro Y, et al:
Discovery of small-molecule inhibitors of Bcl-2 through
structure-based computer screening. J Med Chem. 44:4313–4324. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oliver CL, Miranda MB, Shangary S, et al:
(-)-Gossypol acts directly on the mitochondria to overcome Bcl-2-
and Bcl-X(L)-mediated apoptosis resistance. Mol Cancer Ther.
4:23–31. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Blackstaffe L, Shelley MD and Fish RG:
Cytotoxicity of gossypol enantiomers and its quinone metabolite
gossypolone in melanoma cell lines. Melanoma Res. 7:364–372. 1997.
View Article : Google Scholar
|
|
14
|
Qui J, Levin LR, Buck J and Reidenberg MM:
Different pathways of cell killing by gossypol enantiomers. Exp
Biol Med (Maywood). 227:398–401. 2002.
|
|
15
|
Wolter KG, Wang SJ, Henson BS, et al:
(-)-gossypol inhibits growth and promotes apoptosis of human head
and neck squamous cell carcinoma in vivo. Neoplasia. 8:163–172.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reed JC: Bcl-2 and the regulation of
programmed cell death. J Cell Biol. 124:1–6. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Porter AG and Jänicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mego M: Telomerase inhibitors in
anticancer therapy: gossypol as a potential telomerase inhibitor.
Bratisl Lek Listy. 103:378–381. 2002.
|
|
19
|
Balci A, Sahin FI and Ekmekci A: Gossypol
induced apoptosis in the human promyelocytic leukemia cell line HL
60. Tohoku J Exp Med. 189:51–57. 1999. View Article : Google Scholar
|
|
20
|
Tamir S, Zuris JA, Agranat L, et al:
Nutrient-deprivation autophagy factor-1 (NAF-1): biochemical
properties of a novel cellular target for anti-diabetic drugs. PLoS
One. 8:e612022013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang M, Liu H, Guo R, et al: Molecular
mechanism of gossypol-induced cell growth inhibition and cell death
of HT-29 human colon carcinoma cells. Biochem Pharmacol. 66:93–103.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ergun MA, Konac E, Erbas D and Ekmekci A:
Apoptosis and nitric oxide release induced by thalidomide, gossypol
and dexamethasone in cultured human chronic myelogenous leukemic
K-562 cells. Cell Biol Int. 28:237–242. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kvansakul M and Hinds MG: Structural
biology of the Bcl-2 family and its mimicry by viral proteins. Cell
Death Dis. 4:e9092013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Czabotar PE, Westphal D, Dewson G, et al:
Bax crystal structures reveal how BH3 domains activate Bax and
nucleate its oligomerization to induce apoptosis. Cell.
152:519–531. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chang JS, Hsu YL, Kuo PL, Chiang LC and
Lin CC: Upregulation of Fas/Fas ligand-mediated apoptosis by
gossypol in an immortalized human alveolar lung cancer cell line.
Clin Exp Pharmacol Physiol. 31:716–722. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoon O and Roh J: Downregulation of KLF4
and the Bcl-2/Bax ratio in advanced epithelial ovarian cancer.
Oncol Lett. 4:1033–1036. 2012.PubMed/NCBI
|
|
27
|
Mohammad RM, Wang S, Aboukameel A, Chen B,
Wu X, Chen J and Al-Katib A: Preclinical studies of a nonpeptidic
small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol]
against diffuse large cell lymphoma. Mol Cancer Ther. 4:13–21.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Maurya SK, Tewari M, Sharma B and Shukla
HS: Expression of procaspase 3 and activated caspase 3 and its
relevance in hormone-responsive gallbladder carcinoma chemotherapy.
Korean J Intern Med. 28:573–578. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kasten-Pisula U, Windhorst S, Dahm-Daphi
J, Mayr G and Dikomey E: Radiosensitization of tumour cell lines by
the polyphenol Gossypol results from depressed double-strand break
repair and not from enhanced apoptosis. Radiother Oncol.
83:296–303. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bushunow P, Reidenberg MM, Wasenko J, et
al: Gossypol treatment of recurrent adult malignant gliomas. J
Neurooncol. 43:79–86. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nielsen OS, Judson I, van Hoesel Q, et al:
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A
multicentre phase II study of the EORTC Soft Tissue and Bone
Sarcoma Group. Eur J Cancer. 36:61–67. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Garcia-Carbonero R, Supko JG, Manola J, et
al: Phase II and pharmacokinetic study of ecteinascidin 743 in
patients with progressive sarcomas of soft tissues refractory to
chemotherapy. J Clin Oncol. 22:1480–1490. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kapoor S: Attenuating effect of gossypol
on tumor growth in systemic malignancies. Cell Biochem Biophys.
67:1551–1552. 2013. View Article : Google Scholar : PubMed/NCBI
|
